Objective: Emerging research suggests links between menopausal hot flashes and cardiovascular risk. The mechanisms underlying these associations are unclear due, in part, to the incomplete understanding of the physiology of hot flashes. We aimed to examine the longitudinal associations between hot flashes/night sweats and both inflammatory and hemostatic markers, controlling for cardiovascular risk factors and estradiol concentrations.
V asomotor symptoms (VMS; hot flashes and/or night sweats) are experienced by most women transitioning through menopause. 1 VMS are associated with sleep disturbance, 2 depressed mood, 3 and overall decrements in physical, social, and emotional quality of life. 4 Most women with menopausal symptoms, principally VMS, seek treatment for them. 5 Despite their prevalence and impact on women's lives, the physiology of VMS is not well understood. Leading etiologic models cite VMS as thermoregulatory heat dissipation events occurring in the context of the menopausal withdrawal of gonadal hormones. 6 However, many other central and peripheral systems have been implicated in VMS, and the need for better understanding of the physiology of VMS has been recognized. 7 In addition to the quality of life implications of VMS, some evidence, albeit not entirely consistent, links VMS to cardiovascular risk. 8 In the Women's Health Initiative 9 and the Heart and Estrogen/Progestin Replacement Study, 10 older postmenopausal women with moderate-to-severe VMS at the study baseline were at greatest cardiovascular risk with hormone use. Our findings from the Study of Women's Health Across the Nation (SWAN) Heart Study further showed that midlife women with hot flashes had indices of greater subclinical cardiovascular disease (CVD), including poorer endothelial function, 11 greater aortic calcification, 11 and greater intima media thickness, 12 than did women without hot flashes. Others have found similar findings for endothelial function. 13 Associations generally persist with adjustment for standard cardiovascular risk factors.
The reason(s) for the links between VMS and cardiovascular risk is not fully understood. One study has suggested that hot flash severity may be associated with alterations in inflammatory processes. 14 Altered inflammation and hemostasis, two interrelated systems, 15 play key roles in the pathogenesis of CVD. These alterations have been related, in many cases, prospectively, to CVD risk. 16 In fact, the endothelium, dysfunction of which has been linked to VMS, plays a central role in regulating blood coagulation and inflammation. 17 The primary study aim was to examine the associations between VMS and inflammatory and hemostatic markers in SWAN, a large, longitudinal study of women transitioning through menopause. We assessed the longitudinal relations of VMS to high-sensitivity C-reactive protein (hs-CRP), an acutephase reactant prospectively associated with CVD risk 18 ; the procoagulant/antifibrinolytic hemostatic markers; plasminogen activator inhibitor-1 (PAI-1); tissue plasminogen activator antigen (tPA-ag); and factor VIIc (FVIIc); and the acute-phase reactant protein, fibrinogen, 19 all of which have been linked to CVD risk. 16, 19, 20 We hypothesized that VMS would be associated with adverse alterations in inflammation and hemostasis after adjusting for potential confounding/explanatory factors (eg, smoking, obesity, and educational attainment) as well as serum estradiol (E 2 ), a gonadal hormone associated with both VMS 21, 22 and inflammation/hemostasis. 23 We also evaluated any modification of these associations by menopausal stage and race/ethnicity, given the importance of these factors to VMS and cardiovascular risk.
METHODS

Sample
SWAN is a multiethnic cohort study designed to characterize the biologic and psychosocial changes over the menopausal transition. Details of SWAN design and recruitment procedures are reported elsewhere. 24 Briefly, each SWAN site recruited non-Hispanic white women and women belonging to a predetermined racial/ethnic minority group (African American women in Pittsburgh, Boston, Michigan, Chicago; Japanese in Los Angeles; Hispanic in New Jersey; Chinese in Oakland area of California). Los Angeles, Pittsburgh, and New Jersey sites used random digitYdialed sampling from the banks of telephone numbers, and Boston, Chicago, Michigan, and Oakland sites selected randomly from the lists of names or household addresses. Select sites supplemented primary sampling frames to obtain adequate numbers of racial/ethnic minority women. SWAN protocols were approved by the institutional review boards at each site, and each participant provided written informed consent.
Baseline eligibility criteria for SWAN included being aged 42 to 52 years, having an intact uterus and one or more ovaries, not being pregnant or lactating, not using oral contraceptives or hormone therapy (HT), and having one or more menstrual cycles in the 3 months before the interview. Seventy-three percent of the women selected were contacted and provided information to determine eligibility; 51% (n = 3,302) of eligible women enrolled. Annual clinic assessments began in 1996 to 1997. This investigation was a longitudinal analysis of the associations between VMS and inflammatory/hemostatic markers from baseline through study visit 7 (visits in which inflammatory/hemostatic markers were assessed).
Of the 3,302 women enrolled in SWAN, 92 women were excluded from this analysis because of a history of stroke/ myocardial infarction at baseline, and 11 women were excluded because of having no data for VMS or hemostatic/ inflammatory markers at any visit. Data were censored during the follow-up period at the time of hysterectomy/oophorectomy (n = 221 participants) or reported stroke/myocardial infarction (n = 55 participants), and data from the visits in which pregnancy or hormone use (HT, oral contraceptives) within the previous year was reported were excluded. Thus, 3,199 women were included in the primary analyses. The women excluded from this analysis had lower education, higher body mass index (BMI), more VMS, higher depressive symptom scores, less physical activity, and higher hs-CRP, PAI-1, tPAag, and fibrinogen concentrations. In addition, these women were more likely to be perimenopausal, parous, nondrinkers, diabetic, and taking cardiovascular, psychotropic, or steroid medications compared with women included in the study (all P's G 0.05).
Design and procedures Vasomotor symptoms
Hot flashes and night sweats were assessed using a questionnaire at each SWAN visit. Women responded to two questions that separately asked how often they experienced (1) hot flashes and (2) night sweats in the past 2 weeks (not at all, 1-5, 6-8, 9-13 d, every day; categorized as none, 1-5, Q6 d in the past 2 wk for analysis). Hot flashes and night sweats were considered separately in all analyses because of the differential pattern of associations of hot flashes versus night sweats with the markers investigated here.
Blood assays
Phlebotomy was performed in the morning after an overnight fast. The participants were scheduled for venipuncture on days 2 to 5 of a spontaneous menstrual cycle. Two attempts were made to obtain a sample at days 2 to 5. If a timed sample could not be obtained (because menstrual cycles became less regular, samples tied to the early follicular phase were not feasible), a random fasting sample was taken within 90 days of the annual visit. Blood was maintained up to 1 hour at 4-C until separated and then frozen (j80-C) and sent on dry ice to the Clinical Laboratory Improvement AmendmentsY certified Clinical Ligand Assay Satellite Services laboratory at the University of Michigan (E 2 ) and Medical Research Laboratories (hs-CRP, PAI-1, tPA-ag, FVIIc, fibrinogen) for analysis. For budgetary reasons, hemostatic/inflammatory assays were completed at baseline and at SWAN study years 1, 3, 4, 5, 6, and 7 for hs-CRP, PAI-1, and tPA-ag, and at baseline and at years 1, 3, 5, and 7 for FVIIc and fibrinogen. Inflammatory/hemostatic markers. hs-CRP, FVIIc activity, PAI-1, tPA-ag, and fibrinogen were measured in plasma. The hs-CRP was quantitated using an ultrasensitive rate immunonephelemetric method (hs-CRP; Dade-Behring, Marburg, Germany). The sensitivity of the assay was 0.03 mg/dL, and the interassay coefficients of variations (CVs) at CRP concentrations of 0.05 and 2.2 mg/dL were 10% to 12% and 5% to 7%, respectively. Fibrinogen and FVIIc were measured in frozen citrated plasma (MLA ELECTRA 1400C; Medical Laboratory Automation Inc., Mt. Vernon, NY) using a turbidimetric detection system. Fibrinogen monthly interassay CVs were 2.3% to 3.5% and 2.6% to 3.6% at mean concentrations of 250 and 140 mg/dL, respectively, and FVIIc monthly interassay CVs were 7.8%, 5%, and 4% for mean activities of 8%, 45%, and 99%, respectively. PAI-1 was measured with a sandwich procedure using a solid-phased monoclonal antibody and enzyme-labeled goat second antiserum for detection (IMUBIND plasma PAI-1 enzyme-linked immunosorbent assay [ELISA]; American Diagnostica, Greenwich, CT). PAI-1 monthly interassay CVs were 5% to 9% and 4% to 9% at mean concentrations of 7 and 22.5 ng/dL, respectively. tPA-ag was measured in plasma using a double antibody in an ELISA (IMUBIND tPA ELISA; American Diagnostica). The assay uses human single-chain tPA as a standard calibrated against an international standard (NIBSAC, Hertfordshire, UK). Monthly interassay CVs were 4.7% to 8.7% and 3.8% to 7.8% at mean concentrations of 5.6 and 11 ng/dL, respectively.
Consistent with published guidelines, 25 hs-CRP values less than 10 were excluded (8.6% of observations). For all other markers, to identify extreme values/those probably reflecting acute illness, values outside the mean T 3 SD after log transformation were excluded (of available observations: 0.65% for PAI-1, 0.95% for tPA-ag, 1.1% for FVIIc, 1.3% for fibrinogen).
Estradiol. E 2 assays were performed on the ACS-180 automated analyzer (Bayer Diagnostics Corporation, Tarrytown, NY) using a double-antibody chemiluminescent immunoassay with a solid-phase antiYimmunoglobulin G conjugated to paramagnetic particles, antiligand antibody, and competitive ligand labeled with dimethylacridinium ester. The E 2 assay modifies the rabbit antiYE 2-6 ACS-180 immunoassay to increase sensitivity, with a lower limit of detection of 6.6 pg/mL and interassay and intra-assay CVs of 10.6% and 6.4%, respectively. 26 Duplicate E 2 assays were conducted, and the results are reported as the arithmetic mean.
Covariates
Race/ethnicity, parity (number of live births; any vs none), and educational attainment (years of completed education categorized as lower than vs college degree or higher) were derived from the SWAN screening interview. Age, smoking status (current vs past/never), 27 depressive symptoms, physical activity, alcohol use, menopause status, and medication use/health conditions were derived from questionnaires and interviews that used standard instruments administered during annual visits. Age, smoking, physical activity, menopause status, and medication use/health conditions were considered as time-varying covariates. Race/ethnicity was determined in response to the question BHow would you describe your primary racial or ethnic group?[ Depressive symptoms were assessed via the Center for Epidemiologic Studies Depression Scale. 28 Physical activity was assessed via a modified Kaiser Permanente Health Plan Activity Survey 29 at baseline and at visits 3, 5, and 6, with visits 1, 4, and 7 values carried forward from the last completed assessment. Alcohol use was the reported current consumption of beer, wine, liquor, or mixed drinks, categorized as any versus none. Menopause status was obtained from reported bleeding patterns over the previous year, categorized as premenopausal (bleeding in the previous 3 mo with no change in cycle predictability in the past year), early perimenopausal (bleeding in the previous 3 mo with a decrease in cycle predictability in the past year), late perimenopausal (G12 and 93 mo of amenorrhea), or postmenopausal (Q12 mo of amenorrhea) at each visit.
Several medications/health conditions were considered. Psychotropic medication use was reported use of medication for a nervous condition (eg, antidepressants) since the last study visit. Diabetes status was the reported diagnosis of or reported use of medications to treat diabetes. Women were censored at the time of stroke or myocardial infarction. Other cardiovascular conditions (hypertension, angina) and use of CVD medications (any reported use of medication for a heart condition, an anticoagulant, or for blood pressure lowering in the past year) were combined into a single variable and were covaried. Steroid and pain medication use was reported (including medications for headaches and arthritis). BMI was derived from annual physical measures.
Data analyses
Baseline differences between included and excluded participants were estimated using the Wilcoxon rank sum test for continuous variables and W 2 tests for categorical variables. Univariate associations between covariates and each marker were estimated at baseline using a linear regression. All variables were examined for conformation to the assumptions of normality, and hs-CRP, FVIIc, PAI-1, tPA-ag, and E 2 were log-transformed to normalize their distributions. Longitudinal associations between hot flashes/night sweats and each inflammatory/hemostatic marker, considered separately, were estimated in a random-intercept linear mixed model. An autoregressive error correlation structure was selected based on the standard model fit statistics. For all log-transformed outcomes, regression coefficients were back-transformed using the formula [100 I (exp (A) j 1)] to calculate the percent change (% change) in the outcome per unit change in the predictor. 30 Models were first adjusted for age and site and then, in addition, for covariates selected based on previously documented associations, with the outcome and present association at P G 0.10. Finally, serum E 2 was added to each covariate-adjusted model along with cycle day of blood draw (in vs out of the 2-to 5-d window). Because cycle day of blood draw and menopause status were collinear (only early perimenopausal and premenopausal women could provide timed sample), they were considered as a composite variable (premenopausal timed sample, premenopausal untimed sample, early perimenopausal timed sample, early perimenopausal untimed sample, late perimenopausal, postmenopausal). For time-varying covariates, values concurrent with the time point of the inflammatory/hemostatic marker were used. Interactions between hot flashes/night sweats and both race/ ethnicity and menopause status in relation to each marker were examined as cross-product terms in both simple and multivariable models. Residual analysis and diagnostic plots were conducted to verify model assumptions of normality. Analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC). All models were two sided, > = 0.05.
RESULTS
At baseline, most participants were premenopausal, nonsmokers, overweight, and without hot flashes or night sweats ( Table 1 ). Baseline factors associated with higher values of most inflammatory/hemostatic markers were Hispanic or African American race/ethnicity, low education, smoking, no alcohol consumption, higher BMI, lower physical activity, higher depressive symptoms, lower serum E 2 , and reporting hot flashes or night sweats ( Table 2 ). Reporting of hot flashes and night sweats increased throughout the follow-up period, from 26.3% (n = 837) and 29% (n = 924) of women reporting hot flashes and night sweats, respectively, at baseline, to 53.5% (n = 943) and 38% (n = 670) of women reporting hot flashes and night sweats, respectively, at annual visit 7.
In age-and site-adjusted longitudinal models, hot flashes were associated with greater tPA-ag, PAI-1, and FVIIc, and for women experiencing hot flashes for 6 or more days in the past 2 weeks, higher hs-CRP and fibrinogen (Table 3) . Associations between hot flashes and tPA-ag (any hot flashes) and FVIIc (hot flashes Q6 d) remained with adjustment for covariates ( No significant interactions between hot flashes or night sweats and menopause status were observed for any of the markers. Furthermore, no interactions were observed between race/ethnicity and hot flashes or night sweats in relation to any marker. The one exception was a significant interaction between race and night sweats in relation to fibrinogen (P = 0.03), whereby the association between night sweats and fibrinogen appeared strongest among Hispanic women (data not shown). Given the large number of interactions tested, few Hispanic participants, lack of suggestion of interactions by race/ethnicity for any of the other markers, and lack of any interactions for hot flashes, this finding must be viewed with caution.
DISCUSSION
These results showed that VMS, particularly hot flashes, were associated with elevated FVIIc and tPA-ag, and these associations persisted after we controlled for potential confounding factors and serum E 2 concentrations. Associations between VMS and hs-CRP, fibrinogen, and, to a lesser extent, PAI-1 were largely explained by their shared risk factors.
These findings may be relevant to understanding the physiology of VMS. VMS may be thermoregulatory events, 0.07 0.01 0.004 G0.0001 0.02 hs-CRP, high-sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor-1; tPA-ag, tissue plasminogen activator antigen; FVIIc, factor VIIc. a hs-CRP, tPA-ag, PAI-1, and FVIIc were log-transformed. Regression coefficients were back-transformed using [100 I (exp (A) j 1)] to calculate the percent change in the outcome associated with a 1-unit change in the predictor and 95% CI. or dramatic heat dissipation events occurring in the context of menopause-related declines in reproductive hormones. 6 However, the understanding of the physiology of hot flashes is incomplete. Other systems have been implicated in hot flashes, including changes in neurotransmitters, the vascular endothelium, and the autonomic nervous system. 31 This study also suggests potential changes in hemostasis associated with VMS. Notably, hemostasis, the vascular endothelium, and the autonomic nervous system are interrelated systems. The vascular endothelium is an important regulator of blood viscosity and coagulation, 17 and vagal stimulation can attenuate procoagulant responses to endotoxin. 32 Thus, this research suggests that hot flashes may be more than an endocrine or a thermoregulatory event, but also an autonomic and vascular event.
These findings may also contribute to the understanding of emerging links between VMS and cardiovascular risk. Although not entirely consistent, 8 several investigations have found VMS to be linked to subclinical CVD 11<13 and, in the context of HT use, to clinical CVD events. 9, 10 For subclinical CVD measures, the most consistent associations are observed between hot flashes and endothelial dysfunction markers. 11, 13 Notably, a key role of the endothelium is regulating blood coagulation and inflammatory responses. 17 In contrast to previous work showing the associations between VMS and cardiovascular risk only apparent with HT use 9,10 or among women in the later postmenopause, 9 associations between VMS and hemostasis were observed in the absence of HT use and across several menopausal stages. These findings are consistent with our previous work 11 showing the relations between hot flashes and subclinical CVD among women earlier in the transition.
Hot flashes were associated with elevated FVIIc and tPA-ag after multivariable adjustment. The reason(s) for the more pronounced associations for FVIIc and tPA-ag is not clear. FVIIc is an important protein in the coagulation cascade, 33 and the antigen to tPA, a fibrolytic protein, is associated with elevated cardiovascular risk among women. 34 In addition, tPA is largely derived from endothelium, 33 notable given previously observed associations between hot flashes and endothelial indices. Thus, the results suggest a clearer set of associations with hemostatic, as opposed to inflammatory, processes. However, this interpretation must be made with caution, because inflammatory and hemostatic processes are interrelated, 15, 16 several of the markers have both roles, and the full range of inflammatory markers was not measured here.
For hs-CRP, PAI-1, and fibrinogen, associations with hot flashes were reduced when controlling for shared risk factors. One important risk factor is overweight/obesity. Overweight/ obesity is a risk factor for VMS, 1 possibly due to body fat's insulating properties. Moreover, overweight/obesity is strongly associated with inflammation and hemostasis. 16 Most women in this cohort, similar to the US population, were overweight/obese. Thus, obesity was an important factor in (although not fully accounting for) the associations between inflammation/hemostasis and VMS.
Another potentially important factor in the links between VMS and inflammatory and hemostatic processes is E 2 . Although oral HT use is associated with prothrombotic/ inflammatory states (eg, elevated CRP), 23 endogenous estrogens have more favorable associations. 35 Furthermore, E 2 withdrawal is likely one precipitating factor for VMS, and lower endogenous E 2 is consistently, although sometimes modestly, 22 associated with VMS. 21 Lower serum E 2 was associated with elevations in most markers assessed here; however, controlling for E 2 did not sizably reduce the associations j 1)] to calculate the percent change in the outcome associated with a 1-unit change in the predictor and 95% CI. h beyond other risk factors. Given that E 2 was assessed yearly, and some of the women probably had fluctuating hormone concentrations, E 2 exposure may not have been fully quantified, and further investigation of E 2 in these associations is merited. However, these findings do not support low E 2 as a primary pathway linking VMS to hemostasis.
Findings were most notable for hot flashes reported 6 or more days in the past 2 weeks. Thus, a larger symptom burden may be more related to adverse health indices. Other work has found only more frequent 12 or severe VMS 9, 10, 13, 14 to be associated with cardiovascular risk and/or inflammation. However, the findings have not been entirely consistent. 11 More detailed VMS measures, such as VMS severity or physiologic VMS measures, were not available in this epidemiologic investigation. Further work with more detailed measures of VMS is important to more clearly identify the symptom thresholds associated with adverse cardiovascular profiles.
Findings were most pronounced for hot flashes and slightly weaker for night sweats. With some notable exceptions, 36 previous evidence suggests more consistent associations between hot flashes and certain cardiovascular risk factors 37 and vascular changes 11,13 than night sweats. Notably, night sweats may be reported less reliably, given their occurrence during sleep, 38 and thereby, their reporting may incorporate more nonYVMS-related factors. Furthermore, whether the physiologies of hot flashes and night sweats are interchangeable has not been demonstrated. Thus, because reported hot flashes and night sweats may not be identical, their associations with hemostatic indices may vary as well.
Several limitations deserve mention. First, although an extensive set of inflammatory/hemostatic markers were assessed here, other relevant markers, such as interleukin-6 or interleukin-8, were not assessed. Future work should consider these markers. Although women with heart disease or stroke were excluded, relevant medical conditions and medications were controlled, and careful consideration of outlying values was undertaken, not all medications were queried, and it is possible that women in this investigation were taking medications or had medical conditions not assessed here that could affect inflammation/hemostasis. The grouping of medical conditions and certain medications, although important to reduce the number of parameters in the model and account for the correlations between these factors, may have masked some important relations and overcontrolled for others. In addition, the large number of markers may have increased the risk of detecting spurious associations. Furthermore, although this was a population-based investigation, SWAN participants may not be fully representative of the US population of midlife women. Although many potential confounders were assessed, given that this is an observational study, the possibility of residual confounding by unmeasured factors (eg, genetic factors) remains. Although this was a longitudinal investigation, the directionality or causal nature of these associations cannot be inferred. Further work in future studies to better understand the precise nature of these relations, as well as any potential clinical significance of these associations, is warranted.
This study had several strengths. It is the first to examine the longitudinal associations between VMS and inflammatory/ hemostatic markers. It investigated a large, longitudinal, community-based population of women transitioning through menopause. It allowed investigation of associations between VMS and inflammatory/hemostatic markers within a woman transitioning through menopause, a considerably stronger design than solely conducting between-woman comparisons that are more vulnerable to confounding. In addition, the sample included women from several different ethnic groups, allowing investigation of the consistency of associations across groups. Moreover, a wide range of potential confounders were assessed and controlled. Finally, this study assessed a wide range of inflammatory/hemostatic markers and across several time points, allowing the investigation of the consistency of associations over time and across markers.
CONCLUSIONS
This study found VMS, particularly frequent hot flashes, to be associated with elevations in tPA-ag and FVIIc, above and beyond relevant risk factors and serum E 2 concentrations. Frequent VMS are experienced by many midlife women and are associated with impairments in quality of life during midlife, yet their underlying physiology, as well as implications for health outcomes, is not fully understood. The findings of the present study are relevant to further understand the physiology of VMS. Furthermore, whether VMS are associated with cardiovascular risk and by what mechanism are currently unclear. These findings may contribute to this emerging work linking this menopausal symptom to cardiovascular risk.
